Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).

Sadeleştirilmiş öğe sayfası
dc.contributor.authorBasaran, Gul
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorKara, Halil
dc.contributor.authorBoler, Deniz
dc.contributor.authorKapucuoglu, Nilgun
dc.contributor.authorUras, Cihan
dc.contributor.authorSaglican, Yesim
dc.contributor.authorInce, Umit
dc.date.accessioned2025-10-16T15:31:05Z
dc.date.issued2015
dc.description.abstractAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago, IL, MAY 29-JUN 02, 2015
dc.identifier.doi10.1200/jco.2015.33.15\_suppl.e11589
dc.identifier.otherWOS:000358036902206
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/8983
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titlePrognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS